Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2015

01-07-2015 | Preclinical study

DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers

Authors: Tereza Vaclová, Gonzalo Gómez-López, Fernando Setién, José María García Bueno, José Antonio Macías, Alicia Barroso, Miguel Urioste, Manel Esteller, Javier Benítez, Ana Osorio

Published in: Breast Cancer Research and Treatment | Issue 2/2015

Login to get access

Abstract

BRCA1 germline mutations increase the lifetime risk of developing breast and ovarian cancers. However, taking into account the differences in disease manifestation among mutation carriers, it is probable that different BRCA1 mutations have distinct haploinsufficiency effects and lead to the formation of different phenotypes. Using lymphoblastoid cell lines derived from heterozygous BRCA1 mutation carriers and non-carriers, we investigated the haploinsufficiency effects of various mutation types using qPCR, immunofluorescence, and microarray technology. Lymphoblastoid cell lines carrying a truncating mutation showed significantly lower BRCA1 mRNA and protein levels and higher levels of gamma-H2AX than control cells or those harboring a missense mutation, indicating greater spontaneous DNA damage. Cells carrying either BRCA1 mutation type showed impaired RAD51 foci formation, suggesting defective repair in mutated cells. Moreover, compared to controls, cell lines carrying missense mutations displayed a more distinct expression profile than cells with truncating mutations, which is consistent with different mutations giving rise to distinct phenotypes. Alterations in the immune response pathway in cells harboring missense mutations point to possible mechanisms of breast cancer initiation in carriers of these mutations. Our findings offer insight into how various heterozygous mutations in BRCA1 could lead to impairment of BRCA1 function and provide strong evidence of haploinsufficiency in BRCA1 mutation carriers.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zhang J, Powell SN (2005) The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 3:531–539PubMedCrossRef Zhang J, Powell SN (2005) The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 3:531–539PubMedCrossRef
2.
go back to reference Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130PubMedCentralPubMedCrossRef Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130PubMedCentralPubMedCrossRef
3.
go back to reference Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L et al (2006) Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24:863–871PubMedCentralPubMedCrossRef Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L et al (2006) Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24:863–871PubMedCentralPubMedCrossRef
4.
go back to reference Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Diez O, Alonso MC, Lazaro C, Blanco I, Sanchez-de-Abajo A, Caldes T et al (2008) The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 14:2861–2869PubMedCrossRef Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Diez O, Alonso MC, Lazaro C, Blanco I, Sanchez-de-Abajo A, Caldes T et al (2008) The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 14:2861–2869PubMedCrossRef
6.
go back to reference Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, van Rensburg EJ, Dunning AM, Love R, Evans G et al (1995) Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11:428–433PubMedCrossRef Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, van Rensburg EJ, Dunning AM, Love R, Evans G et al (1995) Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11:428–433PubMedCrossRef
7.
go back to reference Thompson D, Easton D, Breast Cancer Linkage Consortium (2002) Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11:329–336PubMed Thompson D, Easton D, Breast Cancer Linkage Consortium (2002) Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11:329–336PubMed
8.
go back to reference Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der Heijden I, van der Gulden H, Wientjens E, Pieterse M, Catteau A et al (2011) BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 20:797–809PubMedCrossRef Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der Heijden I, van der Gulden H, Wientjens E, Pieterse M, Catteau A et al (2011) BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 20:797–809PubMedCrossRef
9.
go back to reference Waddell N, Ten Haaf A, Marsh A, Johnson J, Walker LC, kConfab Investigators, Gongora M, Brown M, Grover P, Girolami M, Grimmond S, Chenevix-Trench G et al (2008) BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression. PLoS Gen 4:e1000080CrossRef Waddell N, Ten Haaf A, Marsh A, Johnson J, Walker LC, kConfab Investigators, Gongora M, Brown M, Grover P, Girolami M, Grimmond S, Chenevix-Trench G et al (2008) BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression. PLoS Gen 4:e1000080CrossRef
10.
go back to reference Nikkila J, Parplys AC, Pylkas K, Bose M, Huo Y, Borgmann K, Rapakko K, Nieminen P, Xia B, Pospiech H, Winqvist R (2013) Heterozygous mutations in PALB2 cause DNA replication and damage response defects. Nat Commun 4:2578PubMedCentralPubMedCrossRef Nikkila J, Parplys AC, Pylkas K, Bose M, Huo Y, Borgmann K, Rapakko K, Nieminen P, Xia B, Pospiech H, Winqvist R (2013) Heterozygous mutations in PALB2 cause DNA replication and damage response defects. Nat Commun 4:2578PubMedCentralPubMedCrossRef
11.
go back to reference Grasso F, Giacomini E, Sanchez M, Degan P, Gismondi V, Mazzei F, Varesco L, Viel A, Bignami M (2014) Genetic instability in lymphoblastoid cell lines expressing biallelic and monoallelic variants in the human MUTYH gene. Hum Mol Genet 23:3843–3852PubMedCrossRef Grasso F, Giacomini E, Sanchez M, Degan P, Gismondi V, Mazzei F, Varesco L, Viel A, Bignami M (2014) Genetic instability in lymphoblastoid cell lines expressing biallelic and monoallelic variants in the human MUTYH gene. Hum Mol Genet 23:3843–3852PubMedCrossRef
12.
go back to reference Kote-Jarai Z, Williams RD, Cattini N, Copeland M, Giddings I, Wooster R, tePoele RH, Workman P, Gusterson B, Peacock J, Gui G, Campbell C et al (2004) Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status. Clin Cancer Res 10:958–963PubMedCrossRef Kote-Jarai Z, Williams RD, Cattini N, Copeland M, Giddings I, Wooster R, tePoele RH, Workman P, Gusterson B, Peacock J, Gui G, Campbell C et al (2004) Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status. Clin Cancer Res 10:958–963PubMedCrossRef
13.
go back to reference Kote-Jarai Z, Matthews L, Osorio A, Shanley S, Giddings I, Moreews F, Locke I, Evans DG, Eccles D, Carrier Clinic C, Williams RD, Girolami M et al (2006) Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage. Clin Cancer Res 12:3896–3901PubMedCrossRef Kote-Jarai Z, Matthews L, Osorio A, Shanley S, Giddings I, Moreews F, Locke I, Evans DG, Eccles D, Carrier Clinic C, Williams RD, Girolami M et al (2006) Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage. Clin Cancer Res 12:3896–3901PubMedCrossRef
14.
go back to reference Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, Bove B, Slater C, Zhou Y, Daly M, Howard S, Campbell KS et al (2010) Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res 3:48–61CrossRef Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, Bove B, Slater C, Zhou Y, Daly M, Howard S, Campbell KS et al (2010) Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res 3:48–61CrossRef
15.
go back to reference Feilotter HE, Michel C, Uy P, Bathurst L, Davey S (2014) BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development. PLoS One 9:e100068PubMedCentralPubMedCrossRef Feilotter HE, Michel C, Uy P, Bathurst L, Davey S (2014) BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development. PLoS One 9:e100068PubMedCentralPubMedCrossRef
16.
go back to reference Salmon AY, Salmon-Divon M, Zahavi T, Barash Y, Levy-Drummer RS, Jacob-Hirsch J, Peretz T (2013) Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling. Cancer Prev Res 6:82–90CrossRef Salmon AY, Salmon-Divon M, Zahavi T, Barash Y, Levy-Drummer RS, Jacob-Hirsch J, Peretz T (2013) Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling. Cancer Prev Res 6:82–90CrossRef
17.
go back to reference Conti E, Izaurralde E (2005) Nonsense-mediated mRNA decay: molecular insights and mechanistic variations across species. Curr Opin Cell Biol 17:316–325PubMedCrossRef Conti E, Izaurralde E (2005) Nonsense-mediated mRNA decay: molecular insights and mechanistic variations across species. Curr Opin Cell Biol 17:316–325PubMedCrossRef
18.
go back to reference Okada S, Ouchi T (2003) Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization. J Biol Chem 278:2015–2020PubMedCrossRef Okada S, Ouchi T (2003) Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization. J Biol Chem 278:2015–2020PubMedCrossRef
19.
go back to reference Thomas JE, Smith M, Tonkinson JL, Rubinfeld B, Polakis P (1997) Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. Cell Growth Differ 8:801–809PubMed Thomas JE, Smith M, Tonkinson JL, Rubinfeld B, Polakis P (1997) Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. Cell Growth Differ 8:801–809PubMed
20.
go back to reference Buisson M, Anczukow O, Zetoune AB, Ware MD, Mazoyer S (2006) The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Hum Mutat 27:1024–1029PubMedCrossRef Buisson M, Anczukow O, Zetoune AB, Ware MD, Mazoyer S (2006) The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Hum Mutat 27:1024–1029PubMedCrossRef
21.
go back to reference Roy R, Chun J, Powell SN (2011) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12:68–78PubMedCrossRef Roy R, Chun J, Powell SN (2011) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12:68–78PubMedCrossRef
22.
go back to reference Mulrane L, McGee SF, Gallagher WM, O’Connor DP (2013) miRNA dysregulation in breast cancer. Cancer Res 73:6554–6562PubMedCrossRef Mulrane L, McGee SF, Gallagher WM, O’Connor DP (2013) miRNA dysregulation in breast cancer. Cancer Res 73:6554–6562PubMedCrossRef
23.
go back to reference Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S (2002) The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet 11:2805–2814PubMedCrossRef Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S (2002) The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet 11:2805–2814PubMedCrossRef
24.
go back to reference Anczukow O, Ware MD, Buisson M, Zetoune AB, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S (2008) Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? Hum Mutat 29:65–73PubMedCrossRef Anczukow O, Ware MD, Buisson M, Zetoune AB, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S (2008) Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? Hum Mutat 29:65–73PubMedCrossRef
25.
go back to reference Lovelock PK, Healey S, Au W, Sum EY, Tesoriero A, Wong EM, Hinson S, Brinkworth R, Bekessy A, Diez O, Izatt L, Solomon E et al (2006) Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet 43:74–83PubMedCentralPubMedCrossRef Lovelock PK, Healey S, Au W, Sum EY, Tesoriero A, Wong EM, Hinson S, Brinkworth R, Bekessy A, Diez O, Izatt L, Solomon E et al (2006) Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet 43:74–83PubMedCentralPubMedCrossRef
26.
go back to reference Bouwman P, van der Gulden H, van der Heijden I, Drost R, Klijn CN, Prasetyanti P, Pieterse M, Wientjens E, Seibler J, Hogervorst FB, Jonkers J (2013) A high-throughput functional complementation assay for classification of BRCA1 missense variants. Cancer Discov 3:1142–1155PubMedCrossRef Bouwman P, van der Gulden H, van der Heijden I, Drost R, Klijn CN, Prasetyanti P, Pieterse M, Wientjens E, Seibler J, Hogervorst FB, Jonkers J (2013) A high-throughput functional complementation assay for classification of BRCA1 missense variants. Cancer Discov 3:1142–1155PubMedCrossRef
27.
go back to reference Cousineau I, Belmaaza A (2007) BRCA1 haploinsufficiency, but not heterozygosity for a BRCA1-truncating mutation, deregulates homologous recombination. Cell Cycle 6:962–971PubMedCrossRef Cousineau I, Belmaaza A (2007) BRCA1 haploinsufficiency, but not heterozygosity for a BRCA1-truncating mutation, deregulates homologous recombination. Cell Cycle 6:962–971PubMedCrossRef
28.
go back to reference Huszno J, Budryk M, Kolosza Z, Nowara E (2013) The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients. Oncology 85:278–282PubMedCrossRef Huszno J, Budryk M, Kolosza Z, Nowara E (2013) The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients. Oncology 85:278–282PubMedCrossRef
29.
go back to reference Fan S, Yuan R, Ma YX, Meng Q, Goldberg ID, Rosen EM (2001) Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1. Oncogene 20:8215–8235PubMedCrossRef Fan S, Yuan R, Ma YX, Meng Q, Goldberg ID, Rosen EM (2001) Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1. Oncogene 20:8215–8235PubMedCrossRef
30.
go back to reference Sylvain V, Lafarge S, Bignon YJ (2002) Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol 20:845–853PubMed Sylvain V, Lafarge S, Bignon YJ (2002) Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol 20:845–853PubMed
31.
go back to reference You F, Chiba N, Ishioka C, Parvin JD (2004) Expression of an amino-terminal BRCA1 deletion mutant causes a dominant growth inhibition in MCF10A cells. Oncogene 23:5792–5798PubMedCrossRef You F, Chiba N, Ishioka C, Parvin JD (2004) Expression of an amino-terminal BRCA1 deletion mutant causes a dominant growth inhibition in MCF10A cells. Oncogene 23:5792–5798PubMedCrossRef
32.
go back to reference Coene ED, Gadelha C, White N, Malhas A, Thomas B, Shaw M, Vaux DJ (2011) A novel role for BRCA1 in regulating breast cancer cell spreading and motility. J Cell Biol 192:497–512PubMedCentralPubMedCrossRef Coene ED, Gadelha C, White N, Malhas A, Thomas B, Shaw M, Vaux DJ (2011) A novel role for BRCA1 in regulating breast cancer cell spreading and motility. J Cell Biol 192:497–512PubMedCentralPubMedCrossRef
33.
go back to reference Bi X, Hameed M, Mirani N, Pimenta EM, Anari J, Barnes BJ (2011) Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res 13:R111PubMedCentralPubMedCrossRef Bi X, Hameed M, Mirani N, Pimenta EM, Anari J, Barnes BJ (2011) Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res 13:R111PubMedCentralPubMedCrossRef
34.
go back to reference Skelhorne-Gross G, Reid AL, Apostoli AJ, Di Lena MA, Rubino RE, Peterson NT, Schneider M, SenGupta SK, Gonzalez FJ, Nicol CJ (2012) Stromal adipocyte PPARgamma protects against breast tumorigenesis. Carcinogenesis 33:1412–1420PubMedCrossRef Skelhorne-Gross G, Reid AL, Apostoli AJ, Di Lena MA, Rubino RE, Peterson NT, Schneider M, SenGupta SK, Gonzalez FJ, Nicol CJ (2012) Stromal adipocyte PPARgamma protects against breast tumorigenesis. Carcinogenesis 33:1412–1420PubMedCrossRef
35.
go back to reference Apostoli AJ, Skelhorne-Gross GE, Rubino RE, Peterson NT, Di Lena MA, Schneider MM, SenGupta SK, Nicol CJ (2014) Loss of PPARgamma expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment. Int J Cancer 134:1055–1066PubMedCentralPubMedCrossRef Apostoli AJ, Skelhorne-Gross GE, Rubino RE, Peterson NT, Di Lena MA, Schneider MM, SenGupta SK, Nicol CJ (2014) Loss of PPARgamma expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment. Int J Cancer 134:1055–1066PubMedCentralPubMedCrossRef
36.
go back to reference Millevoi S, Bernat S, Telly D, Fouque F, Gladieff L, Favre G, Vagner S, Toulas C (2010) The c.5242C > A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding. Breast Cancer Res Treat 120:391–399PubMedCrossRef Millevoi S, Bernat S, Telly D, Fouque F, Gladieff L, Favre G, Vagner S, Toulas C (2010) The c.5242C > A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding. Breast Cancer Res Treat 120:391–399PubMedCrossRef
Metadata
Title
DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers
Authors
Tereza Vaclová
Gonzalo Gómez-López
Fernando Setién
José María García Bueno
José Antonio Macías
Alicia Barroso
Miguel Urioste
Manel Esteller
Javier Benítez
Ana Osorio
Publication date
01-07-2015
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3459-3

Other articles of this Issue 2/2015

Breast Cancer Research and Treatment 2/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine